SCHEMBL21361637

SCHEMBL21361637

C[C@H]1CN(CC2CCCCC2)C[C@H](C)CN(S(=O)(=O)N2CCc3cc(Cl)ccc3C2)C[C@@H](C)CN(S(=O)(=O)c2ccc(N(C)C)cc2)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.40
AKR1C3 P42330 2/20 0.38
AKR1C1 Q04828 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
POLB P06746 1/20 0.38
ALOX5 P09917 1/20 0.37
LMNA P02545 1/20 0.36
OPRK1 P41145 3/20 0.35
PGR P06401 2/20 0.35
DRD2 P14416 1/20 0.35
ESR2 Q92731 1/20 0.35
HRH3 Q9Y5N1 2/20 0.35
CD4 P01730 1/20 0.35
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23102170 1.00 PDE4B (0.40) PDE4BAKR1C3AKR1C1MEN1KMT2A
SCHEMBL23102256 1.00 PDE4B (0.40) PDE4BAKR1C3AKR1C1MEN1KMT2A
SCHEMBL21361640 1.00 PDE4B (0.40) PDE4BAKR1C3AKR1C1MEN1KMT2A
SCHEMBL21361533 0.92 OPRK1 (0.39) PDE4BAKR1C3AKR1C1MEN1KMT2A
SCHEMBL21361472 0.91 OPRK1 (0.40) PDE4BAKR1C3AKR1C1MEN1KMT2A
SCHEMBL21361547 0.91 OPRK1 (0.39) PDE4BAKR1C3AKR1C1MEN1KMT2A
SCHEMBL23102257 0.86 OPRK1 (0.37) PDE4BAKR1C3AKR1C1MEN1KMT2A
SCHEMBL21361636 0.86 DRD2 (0.41) PDE4BAKR1C3AKR1C1POLBOPRK1
SCHEMBL26234652 0.86 PDE4B (0.35) PDE4BAKR1C3AKR1C1MEN1KMT2A
SCHEMBL21361553 0.85 AKR1C3 (0.43) PDE4BAKR1C3AKR1C1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 US disclosed
WO-2019178510-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2019-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G PDE4B 3430/4885AKR1C3 4212/4885AKR1C1 4152/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G PDE4B 3457/4885AKR1C3 4231/4885AKR1C1 4151/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G PDE4B 3469/4885AKR1C3 4112/4885AKR1C1 4147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.